Disparities In Cancer Care And Costs At The End Of Life: Evidence From England's National Health Service by Walsh, B. & Laudicella, M.
              
City, University of London Institutional Repository
Citation: Walsh, B. and Laudicella, M. (2017). Disparities In Cancer Care And Costs At 
The End Of Life: Evidence From England's National Health Service. Health Affairs, 36(7), pp. 
1218-1226. doi: 10.1377/hlthaff.2017.0167 
This is the accepted version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  http://openaccess.city.ac.uk/17775/
Link to published version: http://dx.doi.org/10.1377/hlthaff.2017.0167
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
1 
 
Do Disparities in Cancer Care Costs Exist at the End of Life? 
Evidence from the English National Health Service 
 
Abstract 
In universal healthcare systems such as the English NHS, 
equality of access is a core principle and healthcare is free at 
the point of delivery. However little is known about 
socioeconomic disparities in end-of-life healthcare costs. This 
study examines disparities in end-of-life costs. Using data on 
66,061 colorectal, 36,698 breast, 39,329 prostate, and 116,749 
lung cancer patients from the National Cancer Data Repository, 
Hospital Episode Statistics, and the National Schedules of 
Reference Costs, evidence from generalized linear models 
illustrates that disparities exist. Observed differences are 
driven largely by the greater use of emergency inpatient care 
among lower SES patients. Therefore, disparities may be reduced 
through better management of needs through the use of less 
expensive, more effective healthcare. As disparities exist even 
within a system with free healthcare, non-financial barriers 
play key roles in socioeconomic disparities in cancer costs and 
outcomes and further study of these barriers is required. 
2 
 
Introduction 
Cancer presents a substantial burden to societies and healthcare 
systems. In the English National Health Service (NHS), 
colorectal, breast, prostate, and lung cancer cost over £1.5 
billion annually for hospital care alone.
1
 A substantial cost 
burden is observed internationally, with ~5% of all healthcare 
expenditure in the United States and Europe a direct result of 
cancer.
2–4
 A feature of the cancer cost curve is its distinctive 
U-shape distribution; with costs highest at the end of life.
1,5
 
However, a dearth of evidence exists on drivers of end-of-life 
healthcare costs and in particular if socioeconomic disparities 
are observed. This question is arguably of increased importance 
in healthcare systems such as the NHS where equality of access 
is a core principle and healthcare is free at the point of 
delivery, and patients have access to similar quality of care 
according to their needs rather than their willingness to pay. 
In this context, socioeconomic disparities may reflect poor 
management of healthcare needs for lower SES patients and the 
greater use of less appropriate and more expensive healthcare, 
which can affect health outcomes and costs. 
It is well defined that patients with lower socioeconomic 
status (SES) have higher healthcare costs in general, including 
in universal healthcare systems such as the NHS.
6–8
 In England, 
despite lower SES individuals having shorter life expectancy, 
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they have higher lifetime hospital costs.
6
 While differences in 
costs among lower SES individuals may reflect greater need for 
healthcare overall, difference may also be explained by greater 
use of low value, less appropriate care. In the United States, 
there is clear evidence that poorer patients have higher use of 
low value care, i.e. acute care instead of primary care, or 
emergency department (ED) care, relative to higher SES 
patients.
9,10
 This increased use of less appropriate care among 
the poor may be driven by insurance coverage and other financial 
barriers. Yet, in the NHS where no such financial barriers 
exist, lower SES individuals have greater rates of emergency 
care.
6,11
 This is of particular concern for cancer, where one in 
five cancers are diagnosed through emergency presentation in 
England
12–14
 and diagnoses through emergency much higher among 
lower SES groups.
15–17
 This greatly impacts patients’ survival, 
and the types of care they can receive. 
This study examines three important aspects of end-of-life 
care in cancer patients in England. First, we estimate costs of 
care in the last six months of life for colorectal, breast, 
prostate, and lung cancer patients. Second, we examine whether a 
socioeconomic gradient in end-of-life healthcare costs exist, 
controlling for a range of important patient-level 
characteristics. Third, we establish whether any observed 
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disparities are underpinned by the greater use of emergency 
admissions amongst lower SES patients.  
 
Data And Methods 
Data from a population-based, patient-level database which 
combines data from the National Cancer Data Repository (NCDR), 
Hospital Episode Statistics (HES), and the National Schedules of 
Reference Costs (NSRC), were included in this study. This 
dataset is similar to SEER-Medicare in the United States. While 
SEER-Medicare includes data on those aged 65 and over only, this 
dataset includes all cancer patients in England. This dataset 
includes all episodes of care generated by patients between 
April 2006 and March 2011, before and after their cancer 
diagnosis. 
The NCDR provides information on the characteristics of 
patients including tumor site (ICD-10), age at diagnosis, date 
of cancer diagnosis and death. HES collects information on 
patients’ utilization of hospital inpatient and outpatient care 
including date and method of admission and discharge, clinical 
information on diagnoses and care provided (details on the most 
common types of care are provided in the Appendix) and 
geographical information with can be merged with other data 
sources. All NHS hospitals are mandated to report the cost of 
every service delivered to patients. The NSRC includes 
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information on the cost of all inpatient and outpatient services 
accessed by NHS patients. This dataset has been used in recent 
studies to investigate the cost of cancer in England
1,18
 and a 
more detailed explanation of this dataset may be found 
elsewhere.
1
 Previous work has validated the use of HES and NCDR 
in estimating hospital costs for a cancer population, with costs 
in HES very similar to those derived from patient medical 
records.
19
 
In this study, we included all individuals aged 18 and over 
with a recorded diagnosis of colorectal cancer (ICD-10 codes: 
C18, C19, C20), breast cancer (females) (C50), prostate cancer 
(C61), or lung cancer (C34) who died between October 1, 2006 and 
March 31, 2011. These four cancers account for a large 
proportion of diagnosed cancers and healthcare costs in England 
and the United States
1,5
 and equate to almost half of cancer 
incidence in developed countries.
20–22
 We include patients having 
a first cancer diagnosis between 2006 and 2010 to correspond to 
the HES data available, and group patients according to the 
first cancer diagnosis, though patients can have a recurrence or 
a secondary cancer after the first diagnosis and enter end of 
life care. We excluded a small number of patients with improper 
death certificate registrations in line with previous work.
23
 
This study sample allowed for hospital utilization and costs to 
be estimated for all patients for at least six months prior to 
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their death. These costs include the care provided before the 
diagnosis if the latter occurred less than six months from death 
as health utilization, on average, increases prior to 
diagnosis.
12
 The final sample included were 66,061 colorectal, 
36,698 breast, 39,329 prostate, and 116,749 lung cancer 
patients. 
 
Outcome Measures 
The outcome measure in this study was hospital costs in the 
last six months of life. We obtained this variable by combining 
information in HES on patient admissions and costs reported in 
the NSRC. Inpatient cost data are disaggregated at the level of 
Healthcare Resource Group (HRG), similar to Diagnosis-Related-
Group (DRGs), making adjustments for patients’ type of 
admission, length of stay, and access to special services.
1,24,25
 
To cost outpatient activity NSRC costs at the level of 
specialty, type of visit, and patient appointment attendance 
were used. A detailed description of the costing mechanism can 
be found in previous work.
1
 All hospital activity costs were 
estimated at fixed 2010 prices to reduce variability from 
inflation and variation in reporting standards over time.
26
 
Costs were modeled using generalized linear models (GLM) 
with log link and gamma family. GLM estimates account for 
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positively skewed costs in the distribution
27,28
 and in line with 
previous analyses on end-of-life costs.
29
  Not accounting for 
skewness may results in inaccurate estimates. 
In the study, analyses were run firstly on overall hospital 
costs, which includes elective and emergency inpatient, and 
outpatient care. Elective inpatient care corresponds to a pre-
planned/booked admission to hospital. An emergency admission is 
not pre-planned and in these data emergency admissions include 
admissions directly from an ED, an emergency request from a 
General Practitioner, or an emergency transfer from another 
hospital. A small number of patients who received no care were 
included and allocated zero costs. Additionally, analyses were 
run separately on elective inpatient and emergency inpatient 
activity using a two-step approach.  
First, Probit models estimated the probability of having 
any end-of-life elective or emergency inpatient admission. 
Second, GLM analyses of costs were undertaken on those patients 
who had at least one elective or emergency inpatient admission 
respectively.  
Differences in the costs of care by SES were calculated by 
comparing average resource use of patients from different 
quintiles of the income distribution in England. Similar to 
other studies,
6,7,30
 the income deprivation of patients’ Lower 
Super Output Area (LSOA) of residence was used as a proxy for 
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individual income, since the latter is not reported in any 
health database in England.
31
 LSOA are homogeneous small areas 
with a population of 1,500 units and designed to improve the 
reporting of small area statistics in England. Patients were 
grouped into different SES quintiles by using the income domain 
of the 2010 Index of Multiple Deprivation (IMD), which measures 
the proportion of residents in a LSOA relying on mean-tested 
income benefits.
32
 In the analyses, deprivation is aggregated to 
the level of quintile for ease of computation and to facilitate 
interpretation of results. 
 A range of patient characteristics which may impact costs 
were included in the analyses including age at diagnosis (linear 
and squared), year of diagnosis, region, and weighted Charlson 
comorbidity index score. The specific site of the tumor for each 
cancer is also controlled for in all models using ICD-10 4-digit 
codes, providing a greater on the etiology and severity of the 
tumor. Finally, days from diagnosis to death, in linear and 
quadratic form, was included in all models. All statistical 
analyses were undertaken using STATA version 13.
33 
 
Limitations 
There are a number of limitations in this study. Important 
individual-level data such as marital status, household-level 
income, and specific cause of death are not available. Staging 
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information for tumors was incomplete for colorectal and breast 
cancer, and not available for prostate and lung cancer. However, 
days from diagnosis to death is used a proxy for staging in all 
analyses. Little information on type of care provided in an 
outpatient visits exist. Furthermore, the data does not cover 
non-acute forms of care such as primary or palliative care. 
However the majority of end-of-life healthcare costs are 
incurred in hospital for cancer.
34,35 
While high costs of informal 
care have been observed across healthcare systems,
36,37
 no 
information on informal care costs were available for this 
study. The income deprivation of patients’ small area of 
residence may be subject to ecological fallacy. 
 
 
 
Study Results 
Unadjusted end-of-life costs differ across SES groups (Exhibit 
1). Low SES colorectal, breast, and lung cancer patients have 
much higher emergency costs than high SES patients (£6,868 
($10,721) versus £5,399 ($8,428) for colorectal; £5,868 ($9,160) 
versus £4,695 ($7,329) for breast; £5,677 ($8,862) versus £4,894 
($7,640) for lung. Elective inpatient and outpatient end-of-life 
costs show little disparity. Low SES colorectal and breast 
cancer patients, in this sample, survive for fewer days after 
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diagnosis than high SES patients. Low SES prostate and lung 
cancer patients are on average one year and 1.6 years younger at 
diagnosis respectively, than high SES patients. Lung cancer 
patients are on average more deprived. 
Exhibit 2 illustrates differences in adjusted total end-of-
life hospital costs, with results presented as average marginal 
effects following GLM regressions.
38
 The lowest SES quintile had 
£456 ($712), £526 ($821), and £564 ($880) higher costs on 
average compared to the highest SES quintile for colorectal, 
breast, and prostate cancers respectively. The lack of 
differences for lung cancer patients is a consequence of poor 
survival across all groups. 
Average marginal effects from multivariate probit 
regressions in Exhibit 3 show the differences in the probability 
of having any elective or emergency inpatient admission in the 
last six months of life. Low SES patients had a lower 
probability of having an elective admission, and a higher 
probability of having an emergency admission. Compared to the 
highest SES quintile, the lowest SES quintile had a 7 percentage 
point higher probability of an elective admission for colorectal 
and lung cancer. The lowest SES quintile had a 3 percentage 
point higher probability of an emergency admission for breast, 
prostate and lung cancer, and a 6 percentage point higher 
probability of an emergency admission for colorectal cancer. 
11 
 
Average marginal effects following GLM regressions for 
adjusted total elective and emergency costs (for patients who 
had any elective or emergency admissions respectively) are shown 
in Exhibit 4. For elective admissions no differences in costs 
across SES groups for colorectal, breast, and prostate cancer is 
seen. Costs were slightly higher for high SES patients with lung 
cancer. However, for emergency admissions, large differences in 
costs are observed across SES groups. The Lowest SES quintile 
had £693 ($1,082), £726 ($1,132), £701 ($1,094), and £333 ($520) 
higher costs than the highest SES group for colorectal, breast, 
prostate, and lung cancers respectively. 
 A number of other analyses were conducted.
38
 Exhibit A1 
shows that in the final six months of life, the number of 
elective bed days did not differ across SES groups, though lower 
SES patients had a larger number of emergency bed days. Analyses 
show higher SES patients had a greater number of outpatient 
visits, and adjusted end-of-life outpatient costs were slightly 
higher amongst higher SES patients. Exhibit A2 shows patients a 
socioeconomic gradient exists for colorectal, breast, and 
prostate cancers regardless of patients weighted Charlson score. 
Exhibit A3 show that even in the last month of life, a 
socioeconomic gradient is observed for type of care used. 
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Discussion 
While equality of access is a core principle of universal 
healthcare systems such as the English NHS and healthcare is 
free at the point of delivery, this study finds evidence that 
socioeconomic disparities in end-of-life costs still remain. We 
find that end-of-life hospital costs for cancer patients are 
substantial, and lower SES patients have noticeably higher cost. 
This study finds that disparities in costs are due to a greater 
use of emergency care. Disparities in costs remain after 
controlling for patient-level characteristics.  
The study highlighta that much of the observed 
socioeconomic disparities in end-of-life costs may have been 
avoided through better management of healthcare needs through 
the use of elective care rather than emergency care. A 
substitution effect between elective admissions and emergency 
care is likely to exist, with lower SES patients substituting 
emergency care for elective care, more so than the high SES 
patients. Similar disparities were observed in the last month of 
life. The greater use of emergency care is in line with previous 
studies which found lower SES patients had a higher probability 
of diagnoses through emergency presentation.
15
 
As equality and free care at the point of delivery are key 
components of the NHS, the factors generating the observed 
disparities differ to those in market-based healthcare systems. 
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In this context, factors other than financial barriers play key 
roles. Similar quality of care is accessible to all patients 
regardless of their ability to pay in England, treatment 
available to patients is dependent upon meeting cost-
effectiveness criteria, and financial incentives at the 
hospital- and doctor-level are at most minimal. Therefore, any 
disparities in cancer costs are likely explained by failures to 
more effectively manage the care of the patient, resulting in 
the use of less efficient care, particularly by lower SES 
patients. Difficulties accessing elective care may be due to 
undersupply of health services in more deprived areas and 
patients may face longer waiting times.
39
 Organizational costs, 
travel costs, and informal care costs may also play a role.  
A plethora of research has found that disparities in cancer 
survival and mortality exist in England and internationally. 
Disparities are a result of many factors including unhealthier 
behaviors such as smoking
40
 and or lower use of screening.
41–44
 For 
example, while an early stage diagnosis is more likely in 
patients diagnosed via screening or through primary care 
referral (i.e. Two Week Wait referrals), a late stage diagnosis 
is more likely after an emergency presentation to hospital.
45 
These disparities are often placed within the wider social 
determinants of health literature.
46,47
 Evidence shows that one 
year survival can be halved in patients diagnosed via an 
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emergency presentation as compared to other routes
12,16,48
 and one 
in five cancers are diagnosed after an emergency presentation in 
England.
12–14
 Therefore, further work is warranted on the key 
drivers of emergency care rather than primary and/or elective 
and the potential implications of substituting to non-emergency 
healthcare has on patient outcomes and healthcare costs. 
 The findings from this study are relevant to policymakers 
in other healthcare systems more generally. Healthcare costs at 
the end of life constitute a substantial portion of overall 
costs with Approximately 25% of Medicare costs incurred in the 
last year of life,
49
 and a slightly lower proportion in England
35
 
and the Netherlands.
50
 This intensive use of care at the end of 
life is found for cancer patients in England in this study. 
Similar intensive use of care is also seen amongst Medicare 
cancer patients, with 61% being hospitalized, and 10% visiting 
an ED more than once within 30 days of death.
51
 Previous analyses 
have shown that end-of-life healthcare costs for cancer patients 
(aged 65 and over) in England are only half those in Canada and 
the United States.
52
 This may reflect other types of care 
continuum in place, or a greater pecuniary incentive to provide 
to provide intensive care. However, similar use of emergency 
care amongst the poor is seen, with evidence from the United 
States showing EDs are increasingly serving as key healthcare 
for poorer or medically underserved patients, such as 
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individuals with Medicaid.
10 
Additionally, other studies have 
shown emergency cancer surgery rates, often used as a proxy for 
quality of care, are higher amongst the uninsured or Medicaid 
patients
53
 and amongst lower SES patients in England
54 
resulting 
in increased hospital use and costs in both systems. While the 
lack of, or inadequate, insurance acts as a barrier to receiving 
of appropriate healthcare in the United States,
55
 this cannot 
account for disparities in the NHS. Therefore disparities in 
costs manifest in different ways (though use off less 
appropriate care underpins disparities in all cases) and may be 
interpreted differently across healthcare system. 
 
An increasingly key element in the cancer care pathway, 
which may also reduce hospital costs at the end-of-life, such as 
ED care,
56
 is the use of more appropriate palliative care. The 
number of people dying in hospital in England has decreased over 
time, though a substantial proportion of people, especially 
poorer patients, still die in an acute setting.
57
 The proportion 
of cancer patients dying in hospital in England (42%) is twice 
that observed in the US,
52
 though lower than other countries, 
including Canada, where over half of patients die within an 
acute setting.
 52
 Having effective palliative care programs can 
reduce healthcare costs. Earlier palliative care consultation 
during admission to hospital in the United States is associated 
with lower hospital costs.
29,58
 Additionally, effective end-of-
16 
 
life care planning should reflect patients’ preferences 
regarding place of death
59
 irrespective of the healthcare 
system.
52
 However, as other have discussed, it would not be wise 
to simply shift the burden of costs to informal carers.
60
 
Evidence from England highlighting that already, caregivers for 
end-of-life cancer patients spend approximately 10 hours daily 
providing care,
61
 and people in lower SES often feel that they 
have less sufficient support to care for someone dying at home.
62
 
 
 
 
Conclusion 
End-of-life healthcare costs in England are higher amongst lower 
SES patients, even after controlling for patient-level 
characteristics. The socioeconomic gradient observed is largely 
due to the greater use of emergency inpatient care amongst lower 
SES patients, in lieu of more appropriate elective or outpatient 
care. More generally, as disparities exist even within a system 
with free healthcare such as the NHS, factors other than 
financial barriers are likely to play a key role in disparities 
in cancer costs and outcomes, and require further study. 
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Exhibit 1: Descriptive Statistics 
 Lowest 
SES 
Quantile 
Quantile 
2 
Quantile 
3 
Quantile 
4 
Highest 
SES 
Quantile 
Colorectal      
Number of Patients 11,930 13,348 14,381 14,042 12,360 
Mean Age at Diagnosis 73.12 74.55 74.47 74.46 73.71 
Mean Weighted Charlson 
Index score 
5.44 5.40 5.35 5.40 5.44 
Mean number of days from 
diagnosis to death 
478 482 496 500 513 
Mean Elective Cost £3,417 £3,252 £3,442 £3,543 £3,620 
Mean Emergency Cost £6,868 £6,122 £5,816 £5,518 £5,399 
Mean Outpatient Cost £563 £533 £529 £552 £579 
Mean Total Cost £11,138 £10,237 £10,135 £9,958 £9,859 
Breast      
Number of Patients 6,728 7,545 7,917 7,795 6,713 
Mean Age at Diagnosis 70.47 72.20 72.53 72.26 70.67 
Mean Weighted Charlson 
Index score 
5.28 5.03 5.06 5.00 5.06 
Mean number of days from 
diagnosis to death 
775 786 791 804 824 
Mean Elective Cost £2,490 £2,480 £2,236 £2,480 £2,466 
Mean Emergency Cost £5,868 £5,444 £5,084 £4,859 £4,695 
Mean Outpatient Cost £648 £572 £582 £581 £625 
Mean Total Cost £9,307 £8,855 £8,298 £8,253 £8,131 
Prostate      
Number of Patients 6,262 7,698 8,613 8,817 7,939 
Mean Age at Diagnosis 76.24 77.25 77.69 77.37 77.19 
Mean Weighted Charlson 
Index score 
5.58 5.50 5.47 5.42 5.46 
Mean number of days from 
diagnosis to death 
757 751 771 760 775 
Mean Elective Cost £9,637 £8,786 £8,791 £8,388 £8,218 
Mean Emergency Cost £1,836 £1,523 £1,719 £1,753 £1,782 
Mean Outpatient Cost £6,912 £6,330 £6,089 £5,676 £5,560 
Lung      
Number of Patients 30,089 26,465 23,728 20,549 15,918 
Mean Age at Diagnosis 71.19 72.13 72.76 72.85 72.80 
Mean Weighted Charlson 
Index score 
5.35 5.31 5.28 5.31 5.34 
Mean number of days from 
diagnosis to death 
254 249 250 255 264 
Mean Elective Cost £1,959 £2,081 £2,127 £2,105 £2,184 
Mean Emergency Cost £5,677 £5,339 £5,136 £4,937 £4,894 
Mean Outpatient Cost £671 £643 £640 £660 £683 
Mean Total Cost £8,547 £8,332 £8,196 £7,986 £8,040 
 
